CA-TETRATE
12.4.2022 14:09:16 CEST | Business Wire | Press release
Tetrate, founded by creators and maintainers of Istio and Envoy, today announced that Istio service mesh and Envoy proxy now support the Arm® Neoverse™ platform. Arm is the leading technology provider of processor IP and its designs have enabled more than 215 billion chips. Neoverse support enables widely used open source software projects to run faster, with less energy usage and lower total cost of ownership.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220412005425/en/
Neoverse is available on a wide range of cloud environments and for large-scale data center environments. Neoverse implementations include AWS Graviton2 processor-based Elastic Compute Cloud (Amazon EC2) instances, which offer a price/performance improvement of up to 40% over comparable x86-based instances.
“The diversity of applications is rapidly changing, and Arm is addressing the growing need for increased performance to take on compute-intensive workloads like service mesh,” said Bhumik Patel, director of ecosystem development, Infrastructure Line of Business, Arm. “By partnering with Tetrate to add Istio and Envoy support to Neoverse based platforms, we can bring better application performance, reduced energy consumption and lower TCO to customers of this industry-leading service mesh software.”
Neoverse is particularly well suited for complex workloads such as machine learning, AI, and now, service mesh . For example, AWS previewed Amazon EC2 instances powered by next-generation AWS Graviton3 processors, which will provide up to 25% better performance for compute-intensive workloads compared to current generation instances powered by Graviton2. AWS Graviton3 processors will deliver up to 2x higher floating-point performance for scientific and machine learning workloads, and will provide 50% higher memory bandwidth versus Graviton2-based instances to improve the performance of memory-intensive applications like scientific computing.
“We at Tetrate are seeing larger and more complex service mesh deployments that demand innovative solutions for meeting SLAs cost-effectively from edge to the cloud,” said Saptak Sen, vice president of Strategic Alliances at Tetrate. “We are proud to work with Arm, AWS, and the rest of the Envoy and Istio communities to help our customers in government, finance, ecommerce, and other markets make their mesh implementations more consistent, flexible, and scalable.”
Why Faster Performance is Important for Service Mesh
A service mesh is made up of microservices software instances which are created and destroyed to meet the capacity needs of an application at runtime. Each service instance is accompanied by a proxy instance, and messages between services are routed through the proxy instances.
Each message between services, or between services and the control plane, is authenticated, authorized, and encrypted/decrypted, boosting security. All of this work is compute-intensive, and encryption and decryption in particular are numerically intensive. Faster performance from the underlying hardware infrastructure can make a tremendous difference in the responsiveness of the service mesh.
Istio is the leading service mesh, and Istio software includes an extended version of the Envoy proxy. Tetrate is optimizing Istio and the Envoy proxy for performance. Neoverse supports these efforts and gives a solid boost to Istio and Envoy performance. Accelerating these software projects also yields higher performance when running Tetrate’s industry-leading service mesh management software, Tetrate Service Bridge.
How Istio Service Mesh Delivers for Government and Industry
Istio service mesh, accelerated by Arm Neoverse on multiple platforms, supports a number of benefits important to government and industry:
- Security . Service mesh performs authentication, authorization, and encryption/decryption on every communication among service instances and with the control plane, enhancing security. Neoverse speeds the necessary processing, including numerical processing for encryption and decryption.
- Agility . Service mesh supports rapid software development using continuous integration/continuous delivery (CI/CD) approaches. Neoverse provides a platform for accelerated performance, which can be managed and enhanced across software updates.
- Business continuity . With service mesh, architects can create applications that can fail over from on-premises to cloud, from one availability zone in the cloud to another, and even from one cloud to another. Neoverse support is available on all these platforms, giving applications consistent performance optimization across all deployment targets.
Download Arm-Ready Versions of Istio
Those interested can download Arm-ready versions of Istio from Tetrate Labs. Options include a FIPS version, compliant with Federal Information Processing Standard (FIPS) 140-2, Security Requirements for Cryptographic Modules. And the number of options for accessing Istio running on Neoverse across multiple platforms is large and growing. To learn more, contact Tetrate .
About Arm
Arm technology is at the heart of a computing and data revolution that is transforming the way people live and businesses operate. Our energy-efficient processor designs and software platforms have enabled advanced computing in more than 215 billion chips and our technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners we are at the forefront of designing, securing and managing all areas of AI-enhanced connected compute from the chip to the cloud.
About Tetrate
Started by Istio founders to reimagine application networking, Tetrate is an enterprise service mesh company managing the complexity of modern, hybrid cloud application infrastructure. Its flagship product, Tetrate Service Bridge, provides an edge-to-workload application connectivity platform to deliver business continuity, agility, and security for enterprises on the journey from traditional monoliths to the cloud. Customers get consistent, baked-in observability, runtime security and traffic management in any environment. Tetrate remains a top contributor to the open-source projects Istio and Envoy Proxy. Find out more at www.tetrate.io .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005425/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
